Quick Takeaways
- ORBIMED ADVISORS LLC filed SCHEDULE 13G/A for Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share (AVTX).
- Disclosed ownership: 8.9%.
- Date of event: 30 Jun 2025.
ORBIMED ADVISORS LLC - 30 Jun 2025 SCHEDULE 13G/A Report for Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share (AVTX)
- Filing Manager
- ORBIMED ADVISORS LLC
- Reporting Manager
- OrbiMed Advisors LLC
- Symbol
- AVTX
- Shares outstanding
- 10,865,169 shares
- Disclosed Ownership
- 967,000 shares
- Ownership
- 8.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Aug 2025, 18:00:00 UTC
- Date of event
- 30 Jun 2025
- Next filing
- 17 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"ORBIMED ADVISORS LLC disclosed 8.9% ownership in Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share (AVTX) on 30 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Aug 2025, 18:00.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 8.9% | 967,000 | 0 | 967,000 | /s/ Carl L. Gordon | Carl L. Gordon / Member of OrbiMed Advisors LLC | |
| OrbiMed Capital GP IX LLC | 6% | 644,667 | 0 | 644,667 | /s/ Carl L. Gordon | Carl L. Gordon / Member |